Onvansertib Helps Overcome Resistance to Zytiga in mCRPC Patients, Interim Phase 2 Data Show

Onvansertib Helps Overcome Resistance to Zytiga in mCRPC Patients, Interim Phase 2 Data Show
Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest. The trial (NCT03414034) is testing onvansertib as an add-on to Zytiga (by Janssen Biotech) and prednisone in men who experienced a rise in their prostate cancer antigen (PSA) levels while receiving the Zytiga-prednisone combination. Findings showed that 72% of patients experienced a drop in their PSA after one cycle of treatment — indicating a positive response to treatment — including all patients positive for the AR-V7 variant, a known marker of resistance to Zytiga and other androgen receptor inhibitors. The data "builds upon the encouraging clinical response seen to date when onvansertib is added to treatment in patients who have developed resistance to androgen receptor signaling inhibitor [ARS] Zytiga," Mark Erlander, PhD, chief scientific officer of Trovagene, said in a press release.
Subscribe or to access all post and page content.